Clinical Trial

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Name: T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis — clinical trial record (NCT07150208)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: THUMB

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Bevicizumab in HER2-low breast cancer with brain metastasis.

Trial Details

NCT Number	NCT07150208
Lead Sponsor	Fudan University
Conditions	Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer
Enrollment	140 participants
Start Date	2025-09
Primary Completion	2027-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2025-09-02